Literature DB >> 32451282

The Dark Side of Arthroplasty: Competing Risk Analysis of Failed Hip and Knee Arthroplasty With Periprosthetic Joint Infection.

Lukas Leitner1, Florian Posch2, Florian Amerstorfer1, Patrick Sadoghi1, Andreas Leithner1, Mathias Glehr1.   

Abstract

BACKGROUND: Increasing total hip (THA) and knee (TKA) arthroplasties inevitably lead to accumulating failed arthroplasty (FA) with periprosthetic joint infections (PJI) and definite treatment recommendations are scarce. Our aims were to evaluate patient and infection site specific risk factors, and to identify case-dependent salvage procedure recommendations.
METHODS: Retrospective analysis was conducted of salvage procedures for FA after PJI (amputation, Girdlestone resection arthroplasty [GRA], arthrodesis, or chronic fistulation [CF]) from 2008 to 2018. Univariable and multivariable modeling of revision and mortality rates, using cumulative incidence competing risk analysis, and Cox proportional hazards models were calculated.
RESULTS: In total, 135 patients (THA 62%; TKA 38%) were diagnosed for FA after PJI, having undergone an average of 3 [1-4] revisions at a mean follow-up of 12.8 [7.8-20.9] years. Forty-four percent of THAs and 55% of TKAs had to be revised following FA, 44% deceased during follow-up, and 16% could be reconverted to an infection-free arthroplasty. GRA revealed significantly higher revision rates than CF (P = .015) for THA. Lower age (P = .003), higher number of revisions before FA (P = .007), more than one microorganism at infection site (P = .034), and GRA (P = .037, only THA) prevailed independent risk factors for revision. Patients' age remained an independent mortality risk factor (P = .001).
CONCLUSION: High-risk patients suffering from FA after THA with poor constitution profit from controlled constitution of CF, reducing the risk for revision surgeries and hospitalization. In case of FA after TKA, data did not allow definite treatment recommendations. We believe that education concerning amputation should be considered early after multiple TKA revisions.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PJI; amputation; arthroplasty; infection; revision

Mesh:

Year:  2020        PMID: 32451282     DOI: 10.1016/j.arth.2020.04.078

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  5 in total

1.  Repeat two-stage exchange arthroplasty for recurrent periprosthetic hip or knee infection: what are the chances for success?

Authors:  A C Steinicke; J Schwarze; G Gosheger; B Moellenbeck; T Ackmann; C Theil
Journal:  Arch Orthop Trauma Surg       Date:  2022-01-04       Impact factor: 3.067

2.  Synovial calprotectin is a reliable biomarker for periprosthetic joint infections in acute-phase inflammation - a prospective cohort study.

Authors:  Igor Lazic; Peter Prodinger; Maximilian Stephan; Alexander T Haug; Florian Pohlig; Severin Langer; Rüdiger von Eisenhart-Rothe; Christian Suren
Journal:  Int Orthop       Date:  2022-05-07       Impact factor: 3.479

3.  Treatment options in PJI - is two-stage still gold standard?

Authors:  Igor Lazic; Christian Scheele; Florian Pohlig; Rüdiger von Eisenhart-Rothe; Christian Suren
Journal:  J Orthop       Date:  2021-01-20

4.  Risk of reinfection after two- or multiple-stage knee revision surgery using superficial vancomycin coating and conventional spacers.

Authors:  Florian Amerstorfer; Martina Schober; Thomas Valentin; Sebastian Klim; Andreas Leithner; Stefan Fischerauer; Mathias Glehr
Journal:  J Orthop Res       Date:  2020-11-04       Impact factor: 3.494

5.  Revision TKA with a distal femoral replacement is at high risk of reinfection after two-stage exchange for periprosthetic knee joint infection.

Authors:  Jan Schwarze; Burkhard Moellenbeck; Christoph Theil; Kristian Nikolaus Schneider; Georg Gosheger; Tom Schmidt-Braekling; Thomas Ackmann; Ralf Dieckmann; Adrien Frommer; Sebastian Klingebiel
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-02-10       Impact factor: 4.342

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.